The patient was considered too unstable to initiate continuous renal replacement therapy
[PMID 38958939, PMID 39976940, PMID 42060879] CONTRAINDICATIONS A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy PRECAUTIONS Kidney disease No dose adjustment is necessary for any degree of renal impairment Liver disease No dose adjustment is necessary for any degree of hepatic impairment Stomach disorders Wegovy slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like Wegovy, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures
Thiu nc khin c t ng, gy ra mn hoc cm gic nng trong
USA 107, 1643216437 (2010)
Provider Comparisons Compare semaglutide, tirzepatide, liraglutide, and dulaglutide side-by-side
No single GLP-1 medication reliably causes fewer side effects across all users, because tolerability is highly individual
